Samir R. Patel - 01 Jan 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Rachelle Jacques, as Attorney-in-Fact for Samir Patel
Issuer symbol
AKTX
Transactions as of
01 Jan 2024
Net transactions value
$0
Form type
3
Filing time
02 Jan 2024, 19:56:38 UTC
Previous filing
30 Nov 2021
Next filing
04 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 2,085,237,500 01 Jan 2024 PranaBio Investments LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 32,500,000 $0.0300 PranaBio Investments LLC
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 25,000,000 $0.0220 PranaBio Investments LLC
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 5,000,000 $0.0220 PranaBio Investments LLC
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 12,500,000 $0.0165 PranaBio Investments LLC
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 50,000,000 $0.0140 PranaBio Investments LLC
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 150,000,000 $0.008500 PranaBio Investments LLC
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 150,000,000 $0.008500 PranaBio Investments LLC
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 96,774,000 $0.000100 PranaBio Investments LLC F1
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 5,000,000 $0.001600 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pre-funded warrants exercisable until exercised in full.
F2 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. The stock option vests and becomes exercisable ratably in three equal installments with the first installment vesting on the date of the first Annual General Meeting ("AGM") following the date of the grant, and with the second and third installments vesting, respectively, on the dates of the second and third AGM's following the date of the grant, subject to the non-employee director's continued service with the Issuer.

Remarks:

See Exhibit 24.1 - Power of Attorney